Neogene Therapeutics Announces Approval of Clinical Trial Application for its First Phase 1 Trial of Novel, Fully-Individualized TCR Therapy to Treat Advanced Solid Tumors

Approval Marks Neogene’s Transition to a Clinical-Stage Company NT-125 is a unique, multi-specific TCR therapy targeting neoantigens specific to each individual cancer patient SANTA MONICA, Calif., and AMSTERDAM, May 10, 2022 – Neogene Therapeutics, Inc., a global biotechnology company focused on discovering, developing, and manufacturing novel, transformative TCR therapies targeting neoantigens in solid cancers, today […]

Clinical Scientist

We offer the opportunity to join a highly dynamic biotech company. You can expect a collaborative environment created by a team with deep scientific expertise and an industrial track-record in T cell therapies. We value pro-active team-players who pursue their goals with dedication, endurance and a daring mindset. If you share our commitment to make […]